p218
Small moleculeexperimental
Clinical trial activity
2 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02885506)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Plasmodium vivaxINHIBITOR
Plasmodium vivax inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- p218
- p218
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03707041 | Phase 1 | Dec 11, 2018 | FGK Clinical Research GmbH, Institute of Tropical Medicine, Belgium, Medicines for Malaria Venture, PrimeVigilance LTD, Sanaria Inc., SGS Life Sciences, Swiss BioQuant A.G., Switzerland, Washington University in St. Louis |
| NCT02885506 | Phase 1 | Aug 1, 2016 | Medicines for Malaria Venture, Richmond Pharmacology |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Medicines for Malaria Venture | Academic/Hospital | 2 | 2 | 1 | 2016 |
| FGK Clinical Research GmbH | For profit | 1 | 0 | 1 | 2018 |
| Institute of Tropical Medicine, Belgium | Academic/Hospital | 1 | 0 | 1 | 2018 |
| PrimeVigilance LTD | For profit | 1 | 0 | 1 | 2018 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2016 |
| Sanaria Inc. | For profit | 1 | 0 | 1 | 2018 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2018 |
| Swiss BioQuant A.G., Switzerland | For profit | 1 | 0 | 1 | 2018 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2018 |
9 organizations
Page 1 / 1